Trends in Inflammatory Bowel Disease Therapy 1999

The proceedings of a symposium organized by AXCAN PHARMA, held in Vancouver, BC, August 27–29, 1999

Inbunden, Engelska, 2000

Av C. Noel Williams, R.F. Bursey, D.G. Gall, F. Martin, R.S. McLeod, L.R. Sutherland, J.L. Wallace, R. F. Bursey, D. G. Gall, R. S. McLeod, L. R. Sutherland, J. L. Wallace

2 179 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

This volume is the proceedings of the symposium `Trends in Inflammatory Bowel Disease Therapy 1999' held in Vancouver, Canada, August 27--29, 1999, and sponsored by the Canadian Association of Gastroenterology, The Crohn's and Colitis Foundation of Canada and Axcan Pharma. It is the seventh international IBD symposium to be held in Canada and focuses on all areas of IBD therapy. Topics include: - Genetics; - Pathogenesis with reference to the role of autoimmunity, bacterial factors and neutrophil--epithelial interactions; - Special clinical problems such as difficult diagnoses and challenges presented by children and the elderly; - Bone disease in IBD; - An overview of current therapy; - A discussion of alternative therapy.

Produktinformation

Utgivningsdatum2000-02-29
Mått155 x 235 x 20 mm
Vikt594 g
FormatInbunden
SpråkEngelska
Antal sidor262
Upplaga2000
FörlagKluwer Academic Publishers
ISBN9780792387626

Tillhör följande kategorier

Sjukdomar och rubbningar inom Medicin
Gastrointestinal och kolorektal kirurgi inom Medicin
Gastroenterologi inom Medicin

Section I: Genetics.- 1 Genetics of Inflammatory bowel disease: where are we?.- 2 Genetics of inflammatory bowel disease: why is it important?.- 3 Genetics of IBD: impact on immune function.- Section II: Pathogenesis.- 4 Bacterial factors in inflammatory bowel disease pathogenesis.- 5 Inflammatory bowel disease: autoimmunity or chronic inflammation?.- 6 Neutrophil—epithelial interactions, and efforts to down-regulate them, in inflammatory bowel disease.- 7 Understanding inflammatory bowel disease at the millennium: tentative answers and future questions.- Section III: Clinical Challenges in Inflammatory Bowel Disease.- 8 Diagnosis of inflammatory bowel disease: an update.- 9 Recent developments in the diagnosis and management of paediatric inflammatory bowel disease.- 10 Inflammatory bowel disease in the elderly.- Section IV: Current Therapy in Inflammatory Bowel Disease.- 11 Induction of remission in ulcerative colitis.- 12 Remission maintenance in ulcerative colitis.- 13 Induction therapy for Crohn’s disease.- 14 Maintenance of remission in Crohn’s disease.- Section V: Bone Disease in Inflammatory Bowel Disease.- 15 Risk factors and prevalence of bone disease in inflammatory bowel disease.- 16 Management of low bone mass in patients with inflammatory bowel disease.- 17 Steroid-induced osteonecrosis in inflammatory bowel disease: Canadian legal status.- Section VI: Alternative Therapy.- 18 Psychotherapy for inflammatory bowel disease: new prospects.- 19 The use of complementary and alternative medicine by patients with inflammatory bowel disease.- 20 Gut inflammation: is there a role for herbal medicines?.- 21 The role of nutrition in the treatment of inflammatory bowel disease.- Section VII: New Therapeutic Approaches.- 22 Antibodies to proinflammatorycytokines.- 23 Immunomodulation of Crohn’s disease.- 24 Application of recombinant DNA technology to the identification of novel therapeutic targets in inflammatory bowel disease.- 25 The use of probiotics in inflammatory bowel disease.